Cytosorbents Corp Leases Disclosure
6. LEASES
The Company has operating leases that primarily relate to operating facilities in both the United States and Germany. The Company leases its operating facilities under operating lease arrangements with varying expiration dates through March 2037. As of December 31, 2025, the remaining lease term of the Company’s operating leases ranges from to twelve years.
Supplemental statement of operations and cash flows related to operating leases is as follows:
For the year ended December 31, | ||||||
| 2025 | | 2024 | |||
(amounts, in thousands) | ||||||
Cash paid in connection with operating leases | $ | 1,696 | $ | 1,684 | ||
Supplemental balance sheet information related to operating leases is as follows:
| December 31, |
| |||||
2025 | 2024 |
| |||||
| | (amounts, in thousands) | |||||
Right-of-use asset | $ | 10,924 | $ | 11,511 | |||
Lease liability – current portion | $ | 541 | 453 | ||||
Lease liability – net of current portion |
| 11,903 |
| 12,444 | |||
Total lease liability | $ | 12,444 | $ | 12,897 | |||
Weighted average discount rate | 9.8 | % | 9.8 | % | |||
Weighted average remaining lease term | 11.4 years | 11.7 years | |||||
Lease Expense
The components of lease expense were as follows:
For the year ended December 31, | ||||||
| 2025 | 2024 | ||||
(amounts, in thousands) | ||||||
Operating lease cost | $ | 1,743 | | $ | 1,701 | |
Variable lease cost |
| 510 |
| 499 | ||
Total lease cost | $ | 2,253 | $ | 2,200 | ||
As of December 31, 2025, the maturities of the lease liabilities are as follows:
2026 | | $ | 1,736 |
2027 |
| 1,777 | |
2028 |
| 1,819 | |
2029 |
| 1,863 | |
2030 |
| 1,907 | |
Thereafter |
| 11,643 | |
Future operating lease payments | 20,745 | ||
Imputed interest | (8,301) | ||
Total lease liability | $ | 12,444 |
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 30, 2026 | Showing above |
| 2024 | Mar 31, 2025 | |
| 2023 | Mar 15, 2024 | |
| 2022 | Mar 9, 2023 | |
| 2021 | Mar 10, 2022 | |
| 2020 | Mar 9, 2021 | |
| 2019 | Mar 5, 2020 | |
About Leases Disclosures
Lease disclosures under ASC 842 provide a comprehensive view of a company's leased asset portfolio, including the split between operating and finance leases, discount rates used to present-value future payments, and the maturity schedule of lease obligations. This section reveals a significant source of off-balance-sheet commitments that were largely hidden before the current standard.
Key signals: the weighted-average discount rate affects the size of recorded lease liabilities — a higher rate reduces the reported obligation, so compare the chosen rate against the company's incremental borrowing rate. The operating versus finance lease mix affects both EBITDA and operating income presentation. Watch the maturity table for concentration risk: large payment cliffs in specific years may create cash flow pressure. Variable lease payments excluded from the liability measurement represent real obligations that do not appear on the balance sheet. Compare total lease costs against prior-year operating lease expense to assess the true economic burden.